Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events

BACKGROUND: IgG4 anbibodies are deficient in stability and may contribute to tumor-associated escape from immune surveillance. We developed an IgG1 backbone anti-programmed cell death protein-1 (PD-1) antibody, penpulimab, which is designed to remove crystallizable fragment (Fc) gamma receptor (FcγR...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhaoliang, Pang, Xinghua, Zhong, Tingting, Qu, Tailong, Chen, Na, Ma, Shun, He, Xinrong, Xia, Dennis, Wang, Max, Xia, Michelle, Li, Baiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272907/
https://www.ncbi.nlm.nih.gov/pubmed/35833116
http://dx.doi.org/10.3389/fimmu.2022.924542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272907/
https://www.ncbi.nlm.nih.gov/pubmed/35833116
http://dx.doi.org/10.3389/fimmu.2022.924542

Ejemplares similares